SEOUL -- South Korean drugmaker SK Biopharmaceuticals started the run-in to its $800 million initial public offering by offering more details of its development pipeline, saying it would begin clinical trials of a cancer treatment next year.
Biotechnology
SK Biopharm highlights drugs pipeline ahead of planned $800m IPO
South Korean drugmaker to start clinical test for anticancer treatment next year
If the float goes as planned, it would be the country's largest IPO since 2017. © Reuters
Read Next
Latest on Biotechnology
